about
Advances in the Isolation of Specific Monoclonal Rabbit Antibodies.Analysis of IgG kinetic stability by differential scanning calorimetry, probe fluorescence and light scattering.Rapid and accurate in silico solubility screening of a monoclonal antibody library.Monoclonal antibodies: technologies for early discovery and engineering.State of play and clinical prospects of antibody gene transfer.Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases.In vitro-engineered non-antibody protein therapeutics.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast CancerCell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysatesTherapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Antibody Isotypes for Tumor Immunotherapy.CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development.Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning.Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.How B-Cell Receptor Repertoire Sequencing Can Be Enriched with Structural Antibody Data.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Delivering natural products and biotherapeutics to improve drug efficacy.Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.Single-Domain Antibodies As Therapeutics against Human Viral Diseases.IgG Fc engineering to modulate antibody effector functions.NMR Detection of Semi-Specific Antibody Interactions in Serum Environments.Intracellular response to process optimization and impact on productivity and product aggregates for a high-titer CHO cell process.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.Novel strategy using tryptic peptide immunoaffinity-based LC-MS/MS to quantify denosumab in monkey serum.Particle Targeting in Complex Biological Media.The Expanding Therapeutic Perspective of CCR5 Blockade.Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.
P2860
Q33639031-BF6B5AB1-20C2-44B2-B652-F5FA9953B8EEQ38611940-27DAB82D-21D9-406D-BB45-490104678DFCQ38622959-32EFCD87-3689-46C3-8002-18703ED9166EQ38633596-34673088-C9ED-4FA2-A2D8-6DF9128C89CBQ38737706-5DFEA553-2766-4019-B698-255169461E94Q38838739-07EC9A83-DCDC-41BC-A546-F4E0F87ABC28Q39002539-66D73E1D-B74D-45FA-BEA2-268122718BCEQ39167522-9B8DD4C4-925D-4A22-8245-5E5D307FF87CQ39433833-72398786-B5F0-42F6-819C-6B1A4A74DF49Q41548612-16DC2A39-15A5-42B4-922C-E9776827A7B4Q41636928-E6B05233-7006-4D71-9723-BDAD91962A1AQ41661268-2249F0CA-2663-4852-A384-69AE4CA313DBQ41697029-41FC097B-F2A1-429E-9368-43DBE5FD925CQ42372842-20F4EC36-ACCB-411D-BD52-5E3264F32F27Q42660171-0F413C1A-8E79-486A-AB58-68A42356999BQ43376023-C83CC334-FEEE-45E9-9758-7221DC3402F9Q44378173-8EFA7630-A257-4446-B08F-BFBBC7C1DD0CQ44852748-2BE0C472-CB12-4944-86ED-87E5E48446BAQ45945330-105C7A4E-E3E3-4C04-AE02-1C90A96D2A2DQ45945673-1FC5E759-6FB2-44D4-975F-F574955BF670Q46242399-275EA900-FCAF-4144-8B64-D9CA92C7D76DQ47113886-8F35DB5F-D613-48A1-8AC7-76CF7EC45853Q47221234-70EDE927-AA65-4410-9B8C-E23C2F7D2F04Q47419190-729F3E9E-9EFD-4CB2-A04A-C9C2462FEAD7Q47548498-3D885A04-25CA-428A-8E39-519C0FE8ECE7Q47554821-32387076-959E-40A6-87F2-67CF09A61CC6Q47593242-80FFF2A8-22CA-4A0C-8DAE-5AEADFEB4EDCQ47626684-D3571B50-72E9-4173-B6BD-190A0B371E57Q47642543-0C108696-CD80-4C44-995C-E18796C81E2FQ47657450-AF70BF49-3CC9-44E2-8205-2431269B8268Q47748470-16178E83-6B50-4EE0-BE5E-B4CDBBC7C014Q47794249-B64F2BBF-344E-41B2-89AA-AB57FB8EB815Q47800556-2256FAF9-AD5E-477F-B400-0614F25329DCQ47942947-0199CBF7-4DFA-4B9E-9BED-1F770107F730Q48089417-37304488-6204-4042-871C-29A3F1C53CD0Q48278134-F4B21AC2-B1B1-4F61-B4DB-A1758468B160Q48689919-3A12AFD8-A604-4A6D-81D6-D6B64A4C40C0Q49210038-7E69FA86-8839-4B4C-9E38-E1087459D6E4Q49592680-CF57385A-DCFE-448B-9171-2540FE761646Q49629406-7646FFD7-3A1C-49DD-8F71-9998D89B1D5C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibodies to watch in 2017
@en
Antibodies to watch in 2017.
@nl
type
label
Antibodies to watch in 2017
@en
Antibodies to watch in 2017.
@nl
prefLabel
Antibodies to watch in 2017
@en
Antibodies to watch in 2017.
@nl
P2860
P1476
Antibodies to watch in 2017
@en
P2093
Janice M Reichert
P2860
P304
P356
10.1080/19420862.2016.1269580
P577
2016-12-14T00:00:00Z